Dr. Chang is a clinical investigator focusing on cardiovascular assessment and outcomes of pediatric-onset systemic lupus erythematosus (pSLE). Her research assesses the utility of various screening modalities, including echocardiography, ambulatory blood pressure monitoring, and tonometry, for the early detection of cardiovascular disease. Her research goals are to develop screening protocols and targeted interventions to prevent pSLE-related cardiovascular morbidity and mortality.
Dr. Mayne is an epidemiologist whose research focuses on preventing cardiovascular disease and promoting healthy behaviors in children and their families. She employs multilevel and longitudinal methods to study how factors at the individual, family, neighborhood, and policy level influence risk factor behaviors and cardiometabolic outcomes. She is also engaged in research to promote innovation in pediatric primary care.
Dr. Glatz is a pediatric interventional cardiologist conducting rigorously designed clinical research. He has formal Masters-level training in study design, epidemiology, and biostatistics. Dr. Glatz has an extensive record of research productivity, including multiple collaborative projects, focused on outcomes research in the content area of pediatric cardiology.
Dr. Rossano's extensive research experience primarily involves the epidemiology and outcomes of cardiovascular disease in children, and multi-institutional collaborative observational and interventional studies. His particular research interests include evaluating the treatment and outcomes of pediatric cardiomyopathy, heart failure, and transplantation.
Dr. Ischiropoulos's research objectives are to develop and test novel therapeutics for long-chain fatty acid oxidation (LCFA) disorders, a collection of inherited metabolic diseases that affect the heart, liver and muscle. A second area of interest is the resolution of the nitric oxide signaling pathways at the proteome level in the cardiovascular and neuronal systems.
Dr. Chorny's research program focuses on nanomedicines as well as drug, cell, and gene delivery systems for treating proliferative disease. His current research specifically focuses on the use of nanoparticle-mediated delivery to solid tumors and site-specific delivery for cardiovascular disease.
Dr. Furth's research focuses on defining risk factors for kidney disease progression in children; characterizing the effect of kidney function decline on neurodevelopment, cognitive abilities and behavior; identifying the prevalence and evolution of cardiovascular disease risk factors, and examining the effects of declining glomerular filtration rate on children’s growth.
Dr. Deardorff’s work integrates patient information with genomics and cell biology to diagnosis and understand rare genetic disease. His research focuses on disorders caused by dysregulation of chromatin or altered translational regulation, specifically, Cornelia de Lange, Coffin-Siris, Skraban-Deardorff and KBG syndromes.